Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors every morning.

It's good to be with you on the Seattle Seahawks Monday, February 9th. I'm Julie Morgan.

Hems and Hers Health is on our biggest movers list ahead of market opening. Hems is down 15% in pre-market action.

We told you Sunday on Wall Street brunch that Hems said it will stop offering a compounded

copycat version of Novo Nordisk Guigovi pill, following pressure from Novo and heightened FDA

scrutiny. In a post on X, the company said it decided to discontinue the

treatment after constructive conversations with industry stakeholders. The move comes after the

commissioner of the FDA said regulators would target companies producing mass market copycat

drugs, which raises broader concerns around compounded GLP1 offerings.

Novo Nordisk is up 7% in pre-market action following the announcement.

Samsung Electronic shares rose as much as 6.4% on Monday after a report that the company will

begin mass production of HBM4 memory chips.

The chips are used as part of the buildout for artificial intelligence infrastructure.

A news outlet reported that the South Korean company plans to ship the semiconductors to

NVIDIA as early as the third week of February. The report said, citing

unnamed industry sources that the HBM chips will be used to power Nvidia's Vera Rubin AI

accelerators. Luckin Coffee continues to take aim at Starbucks. The coffee chain announced the

official inauguration of its 30,000th store on Sunday.

It's the first origin flagship in Shenzhen. China's Luckin coffee is targeting Starbucks high-end

roastery market with a new flagship in the south, marking its first major move from budget stores

that once helped it surpass Starbucks in store count.

Luckin has a vast network across more than 300 Chinese cities and is expanding its presence in Singapore,

...